We are a multidisciplinary team of business operators, biopharma professionals, machine learning engineers, and software developers focused on advancing medical knowledge. Our team is based in Toronto, a city world-renowned for its medical institutions and deep learning research.
Felix is the Founder & CEO of Altis Labs. He believes that deep learning models trained on real-world imaging data can be harnessed to accurately predict patient outcomes to help enable smaller, faster, and more successful clinical trials. Felix and his team have co-published their research with leading clinician scientists at the American Society of Clinical Oncology and in the Journal of Clinical Oncology - Clinical Cancer Informatics. Prior to founding Altis in 2019, Felix led global business development at Enlitic, the first company to apply deep learning to medical imaging that was twice selected as MIT Technology Review's 50 Smartest Companies. Prior to that, he worked at Cambridge Associates focused on venture capital and private equity investments. Felix received his Bachelor of Arts in economics from Colby College.
Shrujal is a medical oncologist. Over the past 15 years, she has worked in academic medicine at Memorial Sloan Kettering Cancer Center and in industry — including as Chief Medical Officer at Iterative Health and Head of Clinical Science at Flatiron — where she focused on novel trial designs and regulatory-grade endpoints that leverage real-world data and AI, particularly computer vision.
Lajhem is a program manager at Verily with an extensive background in health data products and clinical research. Previously, she was a product manager at Verana Health. Prior to Verana, Lajhem managed oncology trials across 21 hospitals at UCSF and was a clinical research supervisor at Memorial Sloan Kettering Cancer Center. Lajhem received her BA from Princeton University, her Master of Science from Columbia University, and her MBA from The Wharton School.
John was global head of data sciences and chief R&D information officer at AstraZeneca, working to rebuild the scientific data environment. Previously, he was in scientific and commercial roles at companies including GSK, Merck, Schrödinger, Riffyn, and Accelrys.
Melissa leads Product & Biostats at Altis. After starting her career at Analysis Group, she joined Flatiron as its first biostatistician in 2014, where she built and led Product and Quantitative Sciences groups to establish use of RWE with FDA. After Roche acquired Flatiron for $1.9 billion, she joined EQRx to lead Clinical Computational Sciences.
Sally is an accomplished entrepreneur, lawyer, and advisor. Prior to co-founding Altis with Felix, Sally founded a venture-backed graphics chip company that she scaled to over $100 million in annual revenue and took public, making her the first female CEO of a publicly-traded semiconductor company. Sally currently serves or formerly served on the boards of Trillium Health Partners (Canada’s largest community hospital network), Intellectual Property Ontario, Enlitic, Hydro One (Canada’s second largest utility company), and the Consumer Technology Association. Sally is a chemical engineer, honorary PhD, and was four times named one of Canada’s 100 most powerful women.
Cameron is a finance professional supporting Altis’ finance & operations function. Prior to joining Altis in 2023, Cameron was an Associate in PwC’s Deals and Valuations group. Cameron received a Bachelor of Commerce from University of Ontario Institute of Technology where he majored in finance.
Shahid is an experienced machine learning engineer focused on applications of deep learning in medical imaging. Prior to joining Altis in 2023, Shahid was a Senior Computer Vision Engineer with Socure, a leading identity verification technology business. Previously, Shahid was with BC Cancer, where he developed a computer vision platform to analyze breast cancer on a genomic level to develop and deliver better targeted treatments. Shahid completed his PostDoc, PhD, and Master of Applied Science in computational biomedical imaging under Prof. Alexander Wong at the University of Waterloo, where he also received his Bachelor of Applied Science.
Jay is an experienced imaging data engineer focused on building data pipelines and quality control tools for the messy real-world imaging data we process. His work accelerates our deep learning model training and deployment. Prior to joining Altis in 2020, he was a neuro-imaging engineer at the Krembil Centre for Neuroinformatics working to facilitate machine learning research. He received his Master of Engineering in biomedical engineering from McGill University.
Matt is an experienced software engineer who has spent over a decade building regulatory-grade medical imaging AI products. Since joining Altis as founding team member in 2019, he has built and scaled our AI platform that has processed millions of images. Prior to joining Altis, Matt was the first and lead engineer at Focal Healthcare. His team built two FDA-cleared products for image-guided prostate therapy. Matt completed his Master and Engineering under Prof. Aaron Fenster at Western University, where he also received his Bachelor of Engineering Science in biomedical engineering.
Keith is Senior Vice President of Commercial and Medical Affairs at ORIC Pharmaceuticals. He brings over 20 years of oncology biopharma experience helping clinical stage programs transition to commercialization. Previously, he held roles in business development, strategy, and marketing at DURECT, Oncopeptides, Prothena, Versartis, Pharmacyclics, and Genentech. Keith received his Bachelor of Art from UC Berkeley and MBA from Vanderbilt University.
Alison has an extensive background in helping biopharma leverage technology to accelerate clinical trials and leads the customer delivery program at Altis. Prior to joining Altis, she deployed software solutions across hundreds of phase 1-3 clinical trials while at Medable, Syneos Health, and IQVIA. Alison received her Bachelor of Science in Pharmacology at McGill University.
Samantha is a full-stack software engineer. Prior to joining Altis in 2022, she was a software engineer at a software design and technology consulting company specializing in financial technology applications. Samantha received her Bachelor of Computing in computer science from Queen’s University.
John has an extensive background in applied artificial intelligence across data modalities and leads Altis’ machine learning team. Prior to joining Altis in 2023, John was the first ML engineer and Head of Artificial Intelligence at Overjet, a leading dental AI platform backed by General Catalyst and Insight Partners. Prior to Overjet, he was a Senior Applied Deep Learning Researcher at DigitalGlobe where he led computer vision projects using satellite imagery in collaboration with the Gates Foundation to mitigate disease spread in rural populations. John previously was a derivatives trader at Deutsche Bank where he managed a $9 billion equity derivatives portfolio and developed proprietary algorithmic trading strategies. John received a Master of Science and MBA from Carnegie Mellon University and a Bachelor of Science from the University of California Santa Barbara.
Oleksandra is an experienced radiologist leading Altis’ radiology team in generating high-quality training data to support our deep learning model development. Prior to joining Altis in 2020, she was lead genitourinary radiologist at LifeScan and conducted research at St. Michael’s Hospital in Toronto. She received her Doctor of Medicine from Donetsk National Medical University.
Duoaud is an experienced business development, clinical technology, and regulatory professional who joined Altis in 2022. He previously led translational research and innovation initiatives at the University Health Network across Princess Margaret Cancer Centre, Toronto General Hospital, and Toronto Western Hospital. He helped establish both the Joint Department of Medical Imaging’s AI Centre and the Peter Munk Cardiac AI Program, managing 30+ academic projects in collaboration with leading AI and clinician scientists. Duoaud received his Master of Science in medical biophysics from the University of Toronto and his Bachelor of Science from York University.
Vignesh is a machine learning engineer focused on leveraging real-world medical imaging data to train robust deep learning models. Prior to joining Altis in 2023, he completed his Masters of Applied Science under Prof. Alexander Wong at the University of Waterloo specializing in computational medical imaging. During his studies, Vignesh also worked on medical imaging software products at Sunnybrook, Agfa, and Synaptive Medical.
Jay has over 20 years of experience in drug development, clinical operations, and strategy across therapeutic areas including oncology, immunology, and neurology. He is the founder and CEO of Ensemble Clinical, an independent consulting firm. Previously, he was VP of Clinical Operations at Prothena Biosciences and, prior to that, worked at Pharmacyclics, Janssen, Elan, and Amgen. He received his Bachelor of Science in Psychological Biology from UCLA and his Master of Science in Artificial Intelligence from Northwestern University.
Helen is the Chief of Staff at Altis Labs. She focuses on driving strategic initiatives and optimizing business operations across all functional areas. Before joining Altis, Helen was a growth-stage investor at Maverix Private Equity focusing on AI, Healthcare, IoT, and SaaS companies across North America. Helen began her career in investment banking at Greenhill & Co. and holds undergraduate degrees in Mathematics from the University of Waterloo and Business Administration from Wilfrid Laurier University.
Felix is the Founder & CEO of Altis Labs. He believes that deep learning models trained on real-world imaging data can be harnessed to accurately predict patient outcomes to help enable smaller, faster, and more successful clinical trials. Felix and his team have co-published their research with leading clinician scientists at the American Society of Clinical Oncology and in the Journal of Clinical Oncology - Clinical Cancer Informatics. Prior to founding Altis in 2019, Felix led global business development at Enlitic, the first company to apply deep learning to medical imaging that was twice selected as MIT Technology Review's 50 Smartest Companies. Prior to that, he worked at Cambridge Associates focused on venture capital and private equity investments. Felix received his Bachelor of Arts in economics from Colby College.
Melissa leads Product & Biostats at Altis. After starting her career at Analysis Group, she joined Flatiron as its first biostatistician in 2014, where she built and led Product and Quantitative Sciences groups to establish use of RWE with FDA. After Roche acquired Flatiron for $1.9 billion, she joined EQRx to lead Clinical Computational Sciences.
Sally is an accomplished entrepreneur, lawyer, and advisor. Prior to co-founding Altis with Felix, Sally founded a venture-backed graphics chip company that she scaled to over $100 million in annual revenue and took public, making her the first female CEO of a publicly-traded semiconductor company. Sally currently serves or formerly served on the boards of Trillium Health Partners (Canada’s largest community hospital network), Intellectual Property Ontario, Enlitic, Hydro One (Canada’s second largest utility company), and the Consumer Technology Association. Sally is a chemical engineer, honorary PhD, and was four times named one of Canada’s 100 most powerful women.
Cameron is a finance professional supporting Altis’ finance & operations function. Prior to joining Altis in 2023, Cameron was an Associate in PwC’s Deals and Valuations group. Cameron received a Bachelor of Commerce from University of Ontario Institute of Technology where he majored in finance.
Shahid is an experienced machine learning engineer focused on applications of deep learning in medical imaging. Prior to joining Altis in 2023, Shahid was a Senior Computer Vision Engineer with Socure, a leading identity verification technology business. Previously, Shahid was with BC Cancer, where he developed a computer vision platform to analyze breast cancer on a genomic level to develop and deliver better targeted treatments. Shahid completed his PostDoc, PhD, and Master of Applied Science in computational biomedical imaging under Prof. Alexander Wong at the University of Waterloo, where he also received his Bachelor of Applied Science.
Jay is an experienced imaging data engineer focused on building data pipelines and quality control tools for the messy real-world imaging data we process. His work accelerates our deep learning model training and deployment. Prior to joining Altis in 2020, he was a neuro-imaging engineer at the Krembil Centre for Neuroinformatics working to facilitate machine learning research. He received his Master of Engineering in biomedical engineering from McGill University.
Matt is an experienced software engineer who has spent over a decade building regulatory-grade medical imaging AI products. Since joining Altis as founding team member in 2019, he has built and scaled our AI platform that has processed millions of images. Prior to joining Altis, Matt was the first and lead engineer at Focal Healthcare. His team built two FDA-cleared products for image-guided prostate therapy. Matt completed his Master and Engineering under Prof. Aaron Fenster at Western University, where he also received his Bachelor of Engineering Science in biomedical engineering.
Alison has an extensive background in helping biopharma leverage technology to accelerate clinical trials and leads the customer delivery program at Altis. Prior to joining Altis, she deployed software solutions across hundreds of phase 1-3 clinical trials while at Medable, Syneos Health, and IQVIA. Alison received her Bachelor of Science in Pharmacology at McGill University.
Samantha is a full-stack software engineer. Prior to joining Altis in 2022, she was a software engineer at a software design and technology consulting company specializing in financial technology applications. Samantha received her Bachelor of Computing in computer science from Queen’s University.
John has an extensive background in applied artificial intelligence across data modalities and leads Altis’ machine learning team. Prior to joining Altis in 2023, John was the first ML engineer and Head of Artificial Intelligence at Overjet, a leading dental AI platform backed by General Catalyst and Insight Partners. Prior to Overjet, he was a Senior Applied Deep Learning Researcher at DigitalGlobe where he led computer vision projects using satellite imagery in collaboration with the Gates Foundation to mitigate disease spread in rural populations. John previously was a derivatives trader at Deutsche Bank where he managed a $9 billion equity derivatives portfolio and developed proprietary algorithmic trading strategies. John received a Master of Science and MBA from Carnegie Mellon University and a Bachelor of Science from the University of California Santa Barbara.
Oleksandra is an experienced radiologist leading Altis’ radiology team in generating high-quality training data to support our deep learning model development. Prior to joining Altis in 2020, she was lead genitourinary radiologist at LifeScan and conducted research at St. Michael’s Hospital in Toronto. She received her Doctor of Medicine from Donetsk National Medical University.
Duoaud is an experienced business development, clinical technology, and regulatory professional who joined Altis in 2022. He previously led translational research and innovation initiatives at the University Health Network across Princess Margaret Cancer Centre, Toronto General Hospital, and Toronto Western Hospital. He helped establish both the Joint Department of Medical Imaging’s AI Centre and the Peter Munk Cardiac AI Program, managing 30+ academic projects in collaboration with leading AI and clinician scientists. Duoaud received his Master of Science in medical biophysics from the University of Toronto and his Bachelor of Science from York University.
Vignesh is a machine learning engineer focused on leveraging real-world medical imaging data to train robust deep learning models. Prior to joining Altis in 2023, he completed his Masters of Applied Science under Prof. Alexander Wong at the University of Waterloo specializing in computational medical imaging. During his studies, Vignesh also worked on medical imaging software products at Sunnybrook, Agfa, and Synaptive Medical.
Helen is the Chief of Staff at Altis Labs. She focuses on driving strategic initiatives and optimizing business operations across all functional areas. Before joining Altis, Helen was a growth-stage investor at Maverix Private Equity focusing on AI, Healthcare, IoT, and SaaS companies across North America. Helen began her career in investment banking at Greenhill & Co. and holds undergraduate degrees in Mathematics from the University of Waterloo and Business Administration from Wilfrid Laurier University.
Shrujal is a medical oncologist. Over the past 15 years, she has worked in academic medicine at Memorial Sloan Kettering Cancer Center and in industry — including as Chief Medical Officer at Iterative Health and Head of Clinical Science at Flatiron — where she focused on novel trial designs and regulatory-grade endpoints that leverage real-world data and AI, particularly computer vision.
Lajhem is a program manager at Verily with an extensive background in health data products and clinical research. Previously, she was a product manager at Verana Health. Prior to Verana, Lajhem managed oncology trials across 21 hospitals at UCSF and was a clinical research supervisor at Memorial Sloan Kettering Cancer Center. Lajhem received her BA from Princeton University, her Master of Science from Columbia University, and her MBA from The Wharton School.
John was global head of data sciences and chief R&D information officer at AstraZeneca, working to rebuild the scientific data environment. Previously, he was in scientific and commercial roles at companies including GSK, Merck, Schrödinger, Riffyn, and Accelrys.
Keith is Senior Vice President of Commercial and Medical Affairs at ORIC Pharmaceuticals. He brings over 20 years of oncology biopharma experience helping clinical stage programs transition to commercialization. Previously, he held roles in business development, strategy, and marketing at DURECT, Oncopeptides, Prothena, Versartis, Pharmacyclics, and Genentech. Keith received his Bachelor of Art from UC Berkeley and MBA from Vanderbilt University.
Jay has over 20 years of experience in drug development, clinical operations, and strategy across therapeutic areas including oncology, immunology, and neurology. He is the founder and CEO of Ensemble Clinical, an independent consulting firm. Previously, he was VP of Clinical Operations at Prothena Biosciences and, prior to that, worked at Pharmacyclics, Janssen, Elan, and Amgen. He received his Bachelor of Science in Psychological Biology from UCLA and his Master of Science in Artificial Intelligence from Northwestern University.